Check for updates

OPEN ACCESS

EDITED BY Qingqing Jiao, The First Affiliated Hospital of Soochow University, China

REVIEWED BY Hydar Ali, University of Pennsylvania, United States Satoshi Tanaka, Kyoto Pharmaceutical University, Japan

*CORRESPONDENCE Songmei Geng I gengsongmei73@163.com Weihui Zeng Zengwh88@126.com

[†]These authors share first authorship

[‡]These authors share senior authorship

RECEIVED 17 April 2023 ACCEPTED 30 May 2023 PUBLISHED 19 June 2023

CITATION

Wang Z, Zhao X, Zhou H, Che D, Du X, Ye D, Zeng W and Geng S (2023) Activation of ryanodine-sensitive calcium store drives pseudo-allergic dermatitis *via* Mas-related G protein-coupled receptor X2 in mast cells. *Front. Immunol.* 14:1207249. doi: 10.3389/fimmu.2023.1207249

COPYRIGHT

© 2023 Wang, Zhao, Zhou, Che, Du, Ye, Zeng and Geng. This is an open-access article distributed under the terms of the **Creative Commons Attribution License** (**CC BY**). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Activation of ryanodine-sensitive calcium store drives pseudo-allergic dermatitis *via* Mas-related G protein-coupled receptor X2 in mast cells

Zhao Wang[†], Xi Zhao[†], Hongmei Zhou, Delu Che, Xiaojie Du, Dan Ye, Weihui Zeng^{*†} and Songmei Geng^{*†}

Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

Mast cell (MC) activation is implicated in the pathogenesis of multiple immunodysregulatory skin disorders. Activation of an IgE-independent pseudo-allergic route has been recently found to be mainly mediated via Mas-Related G protein-coupled receptor X2 (MRGPRX2). Ryanodine receptor (RYR) regulates intracellular calcium liberation. Calcium mobilization is critical in the regulation of MC functional programs. However, the role of RYR in MRGPRX2mediated pseudo-allergic skin reaction has not been fully addressed. To study the role of RYR in vivo, we established a murine skin pseudo-allergic reaction model. RYR inhibitor attenuated MRGPRX2 ligand substance P (SP)-induced vascular permeability and neutrophil recruitment. Then, we confirmed the role of RYR in an MC line (LAD2 cells) and primary human skin-derived MCs. In LAD2 cells, RYR inhibitor pretreatment dampened MC degranulation (detected by βhexosaminidase retlease), calcium mobilization, IL-13, TNF- α , CCL-1, CCL-2 mRNA, and protein expression activated by MRGPRX2 ligands, namely, compound 48/80 (c48/80) and SP. Moreover, the inhibition effect of c48/80 by RYR inhibitor was verified in skin MCs. After the confirmation of RYR2 and RYR3 expression, the isoforms were silenced by siRNA-mediated knockdown. MRGPRX2-induced LAD2 cell exocytosis and cytokine generation were substantially inhibited by RYR3 knockdown, while RYR2 had less contribution. Collectively, our finding suggests that RYR activation contributes to MRGPRX2triggered pseudo-allergic dermatitis, and provides a potential approach for MRGPRX2-mediated disorders.

KEYWORDS

pseudo-allergy, mast cell, degranulation, MRGPRX2, ryanodine receptor, calcium

1 Introduction

Skin hypersensitivity reaction is caused by skin exposure to allergens. Mast cells are regarded as the primary cells that contributes to this process (1–3). Mast cell activation is implicated in a wide spectrum of dermatoses including chronic allergic contact dermatitis and atopic dermatitis (4). Although mast cell activation has been investigated for decades, the primary trigger is believed to be IgE. However, not all patients respond to anti-IgE treatment (5, 6). Moreover, MC secretagogues such as compound 48/80 (c48/80) and neuropeptide substance P (SP) have been applied to induce experimental itch in pseudo-allergic patients and MCs *ex vivo* for decades (7, 8), which does not rely on the IgE-dependent route and was termed pseudo-allergic reaction. Meanwhile, SP was positively correlated with disease severity (9, 10). This indicates the existence of an alternative pathway.

In recent years, Mas-related G protein-coupled receptor X2 (MRGPRX2) was identified to be expressed on skin mast cells and basophils (mouse orthologue is MrgprB2) (11, 12). MRGPRX2 mediates a type of allergic reaction which resembles the symptom of IgE-triggered hypersensitivity reactions (13). The finding of MRGPRX2 explains the phenomenon that patients exhibited skin allergic responses while serum IgE was not elevated. Although MRGPRX2 is deeply mediated in multiple pseudo-allergic skin reactions and is implicated in several skin diseases, the mechanism of MRGPRX2-mediated MC activation is under investigation.

Calcium signaling is crucial for mast cell activation and is implicated in both MC degranulation and the generation of cytokines. Calcium activation patterns by MRGPRX2 and FccRI are drastically diverse (14, 15). MRGPRX2-triggered calcium influx is rapid, while FccRI-mediated calcium activation is relatively delayed. Multiple calcium channels are expressed on human skin MC. Intracellular and extracellular calcium synergistically regulate cellular events, which are regulated by the activation of diverse calcium channels (16). Intracellular calcium release comes from the activation of calcium channels expressed on the sarco/endoplasmic reticulum and mitochondria (16). Inositol 1,4,5-trisphosphate receptor (IP3R) activation-induced intracellular calcium mobilization has been confirmed in both FccRI- and MRGPRX2-mediated routes (17, 18).

Ryanodine receptor (RYR) is one of the primary intracellular calcium release channels apart from IP3R. RYR is known for regulating the contraction of muscles and widely expresses in the sarco/endoplasmic reticulum (19, 20). Ryanodine is a plant component, which has high affinity to RYR. It has divergent roles depending on the concentration, and nanomole concentrations activate RYR by holding it in an open subconductance state, while a higher concentration inhibits the channel (21). Previous publications employed ryanodine as an intracellular depletor (22, 23). With the application of RYR inhibitor, namely, dantrolene, RYR can be more specifically targeted (24). In rat peritoneal mast cells, dantrolene inhibited calcium mobilization and histamine release activated by $Fc \in RI$ aggregation (25). However, it remains unknown if the activation of MRGPRX2 triggered functional regulation of MC relies on RYR-sensitive calcium signals. Thus, in the present study, we aimed

to elucidate the mechanism of calcium signaling by RYR activation, which is elicited by MRGPRX2 activation.

2 Materials and methods

2.1 Mice

C57BL/6 mice (8–10 weeks of age, weighing 20–25 g, male and female) were obtained from the Laboratory Animal Center of Xi'an Jiaotong University. Animal experiments were approved by the Ethics Committee of the Second Affiliated Hospital of Xi'an Jiaotong University (protocol code 2022125, 7 June 2022). Animals were housed under standard conditions (20–25°C, relative humidity 40%, light and dark cycle 12 h) with free access to water and standard dry feed. Mice were randomly divided into a control group and an experimental group.

2.2 Murine Evans blue dye extravasation model

C57BL/6 mice (8-10 weeks of age, weighing 20-25 g, male and female) were intraperitoneally injected with 50 µl of dantrolene (10 mg/ kg in DMSO) or vehicle for 2 consecutive days. Then, each mouse was injected intravenously with 0.2 ml of 0.4% Evans blue dye in saline. After 1 h, mice were anesthetized with an intraperitoneal injection of 80 mg/kg 1% pelltobarbitalum natricum. The thickness of the ear was determined by a vernier caliper. Then, an intradermal injection of SP (50 µM in 20 µl saline) was performed randomly into one side of the ear, and the vehicle (saline) was intradermally injected into the other. After 30 min, the mice were euthanized, ear thickness was measured again, and pictures of the ears were taken. Ear tissues were collected, dried for 24 h at 60°C, and weighed. Tissues were immersed and minced in 300 µl of acetone-saline (7:3). Following by 30 min ultrasonication, tissues were centrifuged for 20 min at 3,000 rpm. Two-hundred-microliter aliquots of the supernatant were seeded into 96-well plates, and the optical density (OD) was read at 620 nm.

2.3 *In vivo* murine skin pseudo-allergic reaction model

C57BL/6 mice (8–10 weeks of age, weighing 20–25 g, male and female) were intraperitoneally injected with 50 µl of dantrolene (10 mg/ kg in DMSO) or saline of the same volume for 2 consecutive days. SP (50 µl of 200 µM SP in saline) or vehicle were intradermally injected into one side of the ear pinna to activate MrgprB2 (murine orthologue of human MRGPRX2). Three hours later, all mice were euthanized and ears were cut and digested with 1.5 mg/ml collagenase type IV (Gibco, Waltham, USA) with DNase I at 10 µg/ml (Roche, Basel, Switzerland) at 37°C in a shaking incubator for 75 min. Cells were filtrated and centrifuged at 400×g for 10 min at 4°C. Pellet-containing cells were processed for flow cytometric analysis.

2.4 Flow cytometry

Cells were incubated with CD11b-PE (Clone:M1/70) and Ly6G-APC (Clone: RB6-8C5) for 45 min, all from liankebio (Hangzhou, China). Live versus dead cells were stained using Zombie YellowTM Fixable viability dye (BioLegend, CA). The data were acquired with a BD FACSCelesta flow cytometer (San Jose, CA) and analyzed by FlowJo software version 10.7.2 (Tree Star Inc., Ashland, OR). Neutrophils were gated as CD11b+Ly6G+ live cells.

2.5 Cell line cultures

The human mast cell Laboratory Allergic Disease 2 (LAD2) cell line was kindly provided by A. Kirshenbaum and D. Metcalfe (NIH, USA). LAD2 cells were cultured with Basal Iscove's medium (Procell Life Science & Technology Co., Ltd., Wuhan, China) supplemented with 10% FCS (VivaCell, Shanghai, China) at 37°C with 5% CO₂. Hemidepletion was performed once a week and supplements of SCF (at 100 ng/ml) (SinoBiological, Beijing, China) and IL-4 (at 20 ng/ml) (Sigma-Aldrich, California, USA) were provided once a week.

2.6 Human skin mast cell isolation

Foreskins were obtained from circumcisions with the written informed consent of the patients or their legal guardians. The study was approved by the Ethics Committee of the Second Affiliated Hospital of Xi'an Jiaotong University (protocol code 2022125, 7 June 2022) and experiments were conducted according to the Declaration of Helsinki Principles. Briefly, skin samples were cut into strips and digested with a 3.5 U/ml dispase (Sigma-Aldrich, California, USA) at 4°C overnight to remove the epidermis. Then, the dermis was chopped and digested with 1.5 mg/ml collagenase type 1 (Gibco, Waltham, USA) and 0.75 mg/ml hyaluronidase type 1-S (Sigma-Aldrich, California, USA) with DNase I at 10 µg/ml (Roche, Basel, Switzerland) at 37°C in a shaking incubator for 75 min. Cells were filtrated and labeled with anti-human c-Kit magnetic microbeads to positively select MC by cell preparation columns (both from Miltenyi Biotec, Bergisch Gladbach, Germany). Purified skin MCs were cultured in Basal Iscove's medium with 10% FCS at the concentration of 5×10^5 /ml, supplemented with SCF (at 100 ng/ml) and IL-4 (at 20 ng/ml) twice a week.

2.7 β-Hexosaminidase release assay

Cells (5×10^4) treated with or without RYR inhibitor (dantrolene, 100 µM, MedChemExpress, Monmouth Junction, USA) were resuspended in 100 µl of PAG-CM buffer (Piperazine-N,N-bis[2ethanesulfonic acid]-Albumin-Glucose buffer containing 3 mM CaCl₂ and 1.5 mM MgCl₂, pH 7.4) and stimulated with vehicle (spontaneous release), compound 48/80 (c48/80) (5 µg/ml, Sigma-Aldrich, St. Louis, Missouri) or substance P (SP) (30 µM, MedChemExpress, Monmouth Junction, USA) for 60 min. Cells were centrifuged and supernatants (SNs) were collected and the pelleted MCs were rapidly frozen with 100 μ l of H₂O. After thawing, 50 μ l of SNs or cell lysates were incubated with the same volume of 4-methyl umbelliferyl-N-acetyl-beta-D-glucosaminide (Sigma-Aldrich, Munich, Germany) solution at 5 μ M in citrate buffer (pH 4.5) for 60 min at 37°C. Sodium carbonate buffer (100 mM; pH 10.7) was added to stop the reaction. Fluorescence intensity was determined at excitation at 355 nm and emission wavelength of 460 nm. % β -hexosaminidase release = [fluorescence intensity SN/ (fluorescence intensity SN + fluorescence intensity lysate)] × 100. The net release was calculated by subtracting spontaneous release.

2.8 Intracellular calcium mobilization assay

Cells (1 × 10⁵ cells/sample) were loaded with 2 µM Fluo-4 AM (Beyotime, Shanghai, China) with 0.02% Pluronic F-127 (Beyotime, Shanghai, China) for 45 min at 37°C in the dark, followed by deesterification for an additional 15 min at room temperature. Then, the cells were washed and resuspended with PAG-CM buffer. For assay with inhibitor, cells were loaded with dantrolene (100 µM) for 15 min before ligand stimulation. Calcium signals were determined using a Fluorescence Spectrophotometer (BMG LABTECH, Ortenberg, Germany) with an excitation wavelength of 494 nm and an emission wavelength of 516 nm. The signal was recorded every 2 s for 2 min at baseline, and additionally 5 min after stimulation.

2.9 RT-qPCR

Briefly, total RNA was isolated with RNA fast200 (Feijie, Shanghai, China) and reverse-transcribed with a SweScript All-in-One First-Strand cDNA Synthesis SuperMix for qPCR (Servicebio, Wuhan, China) as detailed by the manufacturer. PCR was carried out with the 2×Universal Blue SYBR Green qPCR Master Mix (Servicebio, Wuhan, China). Primers were 5'-TTGCGGAGCAAGAGATTCCC and 5'-GGCAGTGCCTCAGCATTTTT for CCL-1, 5'-CCCCAAGCA GAAGTGGGTTC and 5'-TTGGGTTGTGGAGTGAGTGTT for CCL-2, 5'-CTGGGCAGGTCTACTTTGGG and 5'-CTGGAGGCCC CAGTTTGAAT for TNF-a, and 5'-CATCCGCTCCTCAATCCTCT and 5'-GATGCTCCATACCATGCTGC for IL-13. The values were normalized to the housekeeping genes β -actin, cyclophilin B, and GAPDH. The primers were 5'-CTGGAACGGTGAAGGTGACA and 5'-AAGGACTTCCTCTAACAATGCA for β-actin, 5'-AAGATGT CCCTGTGCCCTAC and 5'-ATGGCAAGCATGTGGTGTTT for Cyclophilin B, and 5'-CCTCTGACTTCAACAGCGAC and 5'-TTACTCCTTGGAGGCCATGTG for GAPDH. The $2^{-\Delta\Delta CT}$ method was used to calculate the relative expression levels of the target genes against three housekeeping genes, and the mean expression level of the target gene was calculated by dividing it against reference genes for the analysis.

2.10 ELISA

MCs were seeded at 1×10^6 cells/ml and treated with or without dantrolene (100 µM) for 15 min and then the cells were stimulated with vehicle (spontaneous release), compound 48/80 (c48/80) (5 µg/ml), or substance P (SP) (30 µM) for 24 h. Then, supernatants were collected for IL-13, TNF- α , CCL-1, and CCL-2 measurements. ELISAs were performed according to the manufacturer's instructions (all from Mlbio, Shanghai, China).

2.11 siRNA-mediated knockdown in LAD2 cells

MCs were plated at 1×10^6 /ml and treated with 80 nM of RYR2and RYR3-targeting siRNA or non-targeting siRNA with RNAi-Mate (at 1 µg/ml, GenePharma, Shanghai, China) for 48 h, and employed for downstream analyses. The siRNA sequences were as follows: RYR2 forward: 5'-GGCUCUAAUUAGAGGAAAUTT, RYR2 reverse: 5'-AUUUCCUCUAAUUAGAGCCTT, RYR3 forward: 5'-GCAGAUCAACAUGCUGCUUTT, and RYR3 reverse: 5'-AAGCAGCAUGUUGAUCUGCTT.

2.12 Statistics

Statistical analyses were performed using PRISM 9.0 (GraphPad Software, La Jolla, CA, USA). For the difference between two groups with paired experimental design, comparisons were performed by the *t*-test (when data were normally distributed) or the Wilcoxon matched-pairs signed-rank test (when data were not normally distributed). For the difference between two groups with unpaired experimental design, the Mann–Whitney test was performed. For the difference between more than two groups, comparisons were performed by the RM one-way ANOVA with Dunnett's multiple comparisons tests (when data were normally distributed) or Friedman test with Dunn's multiple comparison test (when data were not normally distributed). When the data were compared to a fixed number, differences between groups were compared using the one-sample *t*-test (normally distributed) or Wilcoxon signed-rank test (not normally distributed). *p* < 0.05 was considered statistically significant.

3 Results

3.1 RYR inhibitor attenuates SP-induced vascular permeability and immune cell infiltration in the murine skin pseudo-allergic reaction model

The mouse ortholog of MRGPRX2 is MrgprB2, which resembles the activation pattern of human MRGPRX2 (11). To verify if the activation of RYR leads to the vascular permeability by MRGPRX2 activation, dantrolene was employed. Dantrolene is an

inhibitor suppressing the activity of all the RYR isoforms (26, 27). We monitored Evans blue dye extravasation by intradermal injection of SP in ear pinna. For mice that received dantrolene intraperitoneally for 2 consecutive days, intradermal injection of SP leads to less Evans blue dye extravasation than that in the control group (Figures 1A, B). By measuring the thickness of the ear pinna, which reflects the swelling of the skin, we found that SP injection induced rapid ear swelling, yet dantrolene pre-treatment inhibited the swelling induced by SP (Figure 1C). Furthermore, we quantified skin immune cell infiltration by flow cytometric analysis. Neutrophil was labeled as CD11+ Ly6G+ cells. SP intradermal injection caused the recruitment of inflammatory cells in the ear pinna. Dantrolene pretreatment inhibited SP-induced neutrophil infiltration (Figures 1D, E).

3.2 RYR inhibitor perturbs MRGPRX2mediated LAD2 degranulation and calcium mobilization

To study the role of RYR in MRGPRX2-mediated MC activation, we detected β -hexosaminidase release in a human MC line, LAD2 cells, to assess MC degranulation. We found that dantrolene significantly inhibited both c48/80 and SP-triggered degranulation (Figures 2A, B). The inhibitory effect of dantrolene on c48/80-triggered degranulation was further verified in human skin-derived MCs (Supplementary Figure 1A).

To confirm if RYR activation regulates calcium mobilization, we detected calcium influx triggered by MRGPRX2 ligands after RYR inhibitor pre-treatment. Calcium signaling activated by MRGPRX2 ligands (both c48/80 and SP) was significantly inhibited by dantrolene (Figures 2C, D). Moreover, the baseline calcium signal was also inhibited by dantrolene before treatment (Supplementary Figure 2). Inhibited calcium mobilization by dantrolene was replicated in human skin-derived MCs (Supplementary Figure 1B). Thus, MRGPRX2-triggered degranulation and calcium mobilization depend on the activation of RYR.

3.3 MRGPRX2 activation-induced cytokine production relies on the activation of RYR

Apart from degranulation, cytokine production is regulated by calcium signal in MCs (28–30). To further determine if RYR is implicated in MRGPRX2-triggered cytokine and chemokine generation, we detected IL-13, TNF- α , CCL-1, and CCL-2 expression. After the inhibition of RYR activity by dantrolene, LAD2 cells were stimulated by MRGPRX2 ligands c48/80 and SP. IL-13, TNF- α , CCL-1, and CCL-2 mRNA generation were perturbed after the application of RYR inhibitor (Figure 3). We also detected selected cytokine mRNA expression in human skinderived MCs triggered by c48/80, and decreased IL-13, TNF- α , CCL-1, and CCL-2 mRNA were detected after dantrolene pretreatment (Supplementary Figure 1C). In accordance with mRNA



(50 μ M) or saline was intradermally injected into one side of the ear. (A–C) Vascular permeability was quantified by Evans blue extravasation, and the thickness of the ear was determined by a vernier caliper (n = 6). (A) Representative photo of Evans blue extravasation in the murine skin anaphylaxis model. (B) Quantification of Evans blue extravasation. (C) Ear tissue thickness after the injection of SP or saline. (D, E) Ear tissue was collected and neutrophil infiltration (CD11b+ Ly6G+ live cells) was determined by flow cytometry (n = 5-7). (D) Representative flow cytometry images. (E) Percentage of neutrophils in the live skin cell population. Data shown are mean \pm SEM. Ctrl.: control, inh.: inhibitor. ns: not significant, *p < 0.05, **p < 0.01.

data, all the cytokine/chemokine detected were downregulated by RYR inhibitor at the protein level (Figure 4).

3.4 RYR3 is required in MRGPRX2mediated LAD2 cell activation, while RYR2 has variable contribution

To further verify the role of RYR in MRGPRX2-mediated MC activation, we selectively silenced the expression of the RYR gene. Three isoforms of *RYRs* have been identified (*RYR1*, *RYR2*, and *RYR3*) (26). To select the RYR isoforms that potentially participate in the functional regulation of LAD2 cells, we compared the expression level of the transcripts based on the GEO dataset (GSE216269) (31). From this dataset, the expression of unstimulated LAD2 cells were selected for assessment; RYR2 and RYR3 showed relatively higher expression (Supplementary Figure 3A). The expression of candidate genes was further

quantified by RT-qPCR in our study. In all three identified isoforms, RYR3 had the highest expression, which was followed by RYR2, and RYR1 was rarely expressed in LAD2 cells (Supplementary Figure 3B). Thus, we selectively knocked down the expression of RYR2 and RYR3, and both RYR2- and RYR3-selective siRNAs resulted in the effective knockdown of their respective targets (Supplementary Figures 3C, D).

Interference with RYR3 suppressed the degranulation by both agonists employed, i.e., c48/80 and SP. RYR2 siRNA also decreased the secretion of LAD2 cells, although it did not reach significance (Figures 5A, B). In terms of calcium mobilization, RYR3-specific siRNA decreased the calcium signal induced by both ligands (Figures 5C, D). RYR2 only significantly inhibited SP-triggered calcium influx; c48/80 had the tendency but did not reach significance.

Then, we attempted to ascertain that MRGPRX2-mediated cytokine generation relies on RYR activation in siRNA KD LAD2 cells. RYR3 downregulated IL-13, TNF- α , CCL-1, and CCL-2



FIGURE 2

RYR inhibitor perturbs MRGPRX2-mediated mast cell degranulation and calcium mobilization. LAD2 cells were treated with RYR inhibitor (dantrolene, 100 μ M) for 15 min and then the cells were stimulated with c48/80 (5 μ g/ml) or SP (30 μ M). (A, B) β -Hexosaminidase release and (C, D) calcium mobilization was determined, respectively. The data are from 7 to 15 independent experiments. ns: not significant, Ctrl.: control, inh.: inhibitor. **p < 0.001, ***p < 0.001, ***p < 0.001.



MRGPRX2 activation-induced cytokine mRNA generation relies on the activation of RYR. Cells were preincubated with or without RYR inhibitor (dantrolene, 100 μ M) for 15 min and stimulated with **(A)** SP (60 μ M) or **(B)** c48/80 (5 μ g/ml). Cytokine mRNA was determined by RT-qPCR. The data were normalized against the cell receiving no inhibitor and stimuli. Data shown are mean \pm SEM of n = 7-11. inh.: inhibitor. *p < 0.05, **p < 0.01.



mRNA synthesis triggered by c48/80 and SP. RYR2 siRNA also downregulated all the cytokine genes detected, while only c48/80 stimulated CCL-1 and CCL-2 significantly decreased (Figure 6).

4 Discuss ion

MRGPRX2-mediated MC activation has drawn much attention recently, due to its non-IgE-dependent feature. Moreover, MRGPRX2-mediated MC activation is implicated in multiple dermatoses, e.g., chronic spontaneous urticaria and atopic dermatitis (1, 32, 33). In the present study, we demonstrate that RYR-sensitive calcium signaling is activated after MRGPRX2 activation. MRGPRX2-mediated MC granule secretion, calcium mobilization, and cytokine generation are inhibited by both RYR inhibitor and siRNA-mediated KD. MRGPRX2 activation is also inhibited by an RYR inhibitor in an *in vivo* mouse skin anaphylaxis model.

The induction of calcium signaling after antigen-specific IgE triggering in mast cells has been noticed for a long time. It has been recognized that the depletion of intracellular calcium stores led to the entry of extracellular calcium (34, 35). Both the activation of intracellular calcium stores and cell membrane-expressing calcium channels contribute to mast cell degranulation and cytokine

production (18, 28). The classical IgE-induced calcium signal was recognized as the production of inositol 1,4,5-trisphosphate (IP3) by phospholipase C γ (36), and the IP3/thapsigargin-sensitive pool from the endoplasmic reticulum (ER) induced the depletion of the intracellular calcium store. Depletion of this pool leads to the influx of external calcium by activating cell membrane expressing calcium channels. The calcium activation pattern was different in FceRI versus MRGPRX2. MRGPRX2-triggered calcium influx is quicker than that triggered by FceRI aggregation (14). This indicates that the calcium activation model in one channel cannot be applied to another. Considering that the intracellular calcium store is the first responder in the calcium signaling events, the ER-expressing calcium signal might be more crucial in MRGPRX2-related MC functional regulation than that in FceRI-mediated mast cell activation.

Intracellular calcium stores in MCs were widely believed to be activated by the IP3 receptor (IP3R) (16, 37, 38). The role of RYR, which is also an ER-expressing calcium channel, was seldom reported. We found that the calcium influx triggered by MRGPRX2 can be effectively inhibited by an RYR inhibitor, namely, dantrolene. The inhibition was consistent across two MRGPRX2 ligands applied, i.e., c48/80 and SP. Although dantrolene can effectively inhibit calcium influx activated by MRGPRX2, the inhibition was not complete. As MRGPRX2



activates multiple calcium channels, the utilization of other calcium channels also contributes to intracellular calcium oscillation, e.g., the activation of IP3R, STIM1, and Orai channels (28, 39). MC degranulation largely depends on calcium signaling, as we have previously reported with IP3R and Orai-dependent SOCE (40). Moreover, the baseline calcium level was dampened after preincubation with an RYR inhibitor (Supplementary Figure 2). Intracellular calcium level normally remains at very low concentrations, which is sufficient for the regulation of numerous basic cellular processes including proliferation, differentiation, and cellular motility (41). The decrease of intracellular calcium level at the resting state indicates that the RYR channel is involved in the maintenance of fundamental cellular function. RYR can be activated by multiple ways, including interaction with L-type calcium channel (dihydropyridine receptor) and activation of various ions (calcium and magnesium) and proteins [protein kinase A, FK506 binding proteins, calmodulin, and calcium/calmodulin-dependent protein kinase II (CaMKII)] (21). L-type calcium channel, which is a storeoperated calcium channel (SOC), has been reported to mediate FceRI aggregation-induced MC activation (42). Moreover, MC activation by both FceRI aggregation and MRGPRX2 activates calcium/calmodulin (43-45).

Previous studies have demonstrated that MC degranulation is regulated by calcium signals. The role of ER-expressing IP3R, STIM1, Orai channels, and TRP channels has been profoundly illuminated in multiple studies (16, 28, 39). The receptors that cannot activate calcium influx cannot trigger degranulation, e.g., ST2/IL-33R, TLR4, or TSLPR (46–49). We found that the RYR inhibitor downregulated MRGPRX2-triggered degranulation. Partial inhibition of MRGPRX2-mediated MC degranulation by RYR inhibitor is consistent with the calcium mobilization data, indicating that the calcium signal might be compensated by other calcium channels.

It is well known that calcium signaling is essential for the generation of multiple proinflammatory cytokines (16, 50). MCs are capable of generating multiple cytokines. Based on our previous studies (51), we selected several cytokine genes to detect in the present study. CCL-1, CCL-2, TNF- α , and IL-13 mRNA and proteins were downregulated by MRGPRX2 activation. Downstream of calcium signaling, multiple signaling pathways including MAPKs and calcineurin-NFAT signaling pathways are activated (40, 52). CCL-1, CCL-2, TNF- α , and IL-13 were all regulated by TAK1, which is the kinase downstream of calcimodulin (53, 54). The role of RYR in the generation of the



cytokines listed was further demonstrated by the knockdown of individual RYR isoforms. Herein, we confirmed the participation of RYR3 in this process.

Finally, we used the mouse cutaneous anaphylaxis model to verify the role of RYR in Mrgprb2 activation *in vivo*. MC degranulation is associated with increased vascular permeability, which leads to vasodilation and vascular leakage. Decreased skin edema and vascular leakage triggered by SP with dantrolene pretreatment demonstrated the role of RYR in MRGPRX2-mediated skin allergy. In terms of immune cell recruitment, which represents the late-phase response following MC activation, the curtailed neutrophil recruitment represents the inhibited inflammation by RYR inhibition. Interestingly, in *ex vivo* studies, the reduction rate of β hexosaminidase release is less than the vascular leakage and immune cell infiltration in *in vivo* studies. Apart from the reason that to trigger a certain symptom needs adequate amount of stimulator, the release of the MC granule could be under the triggering threshold after the inhibition by dantrolene. Moreover, RYR expresses on multiple cell types, e.g., keratinocyte and neutrophils (55, 56). Pre-treatment of dantrolene can also inhibit the activation of RYR on other cells; thus, the inhibition in animal studies was higher than that in *ex vivo* experiments.

In conclusion, MRGRPX2 activation regulates pseudo-allergic reactions, and emerging compounds including FDA-approved drugs were identified as MRGPRX2 ligands. The role of MRGPRX2 is insinuated in the pathogenesis of urticaria, atopic dermatitis, and psoriasis. We identified RYR as a calcium channel, which is activated by MRGPRX2. The activation leads to MC degranulation and the generation of CCL-1, CCL-2, TNF- α , and IL-13. The *ex vivo* studies were verified by RYR isoform knockdown. Moreover, the pivotal role of RYR3 was identified. With the cutaneous anaphylaxis mouse model, we found that

MRGPRX2-induced vascular permeability and immune cell recruitment were impaired by dantrolene. The present study suggests the potential novel therapeutic approaches targeting RYR for the treatment of allergic diseases.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Committee of the Second Affiliated Hospital of Xi'an Jiaotong University. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by the Ethics Committee of the Second Affiliated Hospital of Xi'an Jiaotong University.

Author contributions

Conceptualization, ZW. Investigation, ZW, XZ, HZ, DC, XD, and DY. Data curation, ZW and XZ. Writing—original draft preparation, ZW. Writing—review and editing, ZW, SG, and WZ. Visualization, ZW. Supervision, ZW, SG, and WZ. Project administration, ZW. Funding acquisition, ZW and SG. All authors contributed to the article and approved the submitted version.

References

1. Galli SJ, Gaudenzio N, Tsai M. Mast cells in inflammation and disease: recent progress and ongoing concerns. *Annu Rev Immunol* (2020) 38:49–77. doi: 10.1146/ annurev-immunol-071719-094903

2. Metcalfe DD, Baram D, Mekori YA. Mast cells. *Physiol Rev* (1997) 77(4):1033–79. doi: 10.1152/physrev.1997.77.4.1033

3. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol (2010) 125(2 Suppl 2):S73–80. doi: 10.1016/j.jaci.2009.11.017

4. Ohtsu H, Seike M. Histamine and histamine receptors in allergic dermatitis. Handb Exp Pharmacol (2017) 241:333-45. doi: 10.1007/164_2016_9

5. Berard F, Ferrier Le Bouedec MC, Bouillet L, Reguiai Z, Barbaud A, Cambazard F, et al. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1antihistamine treatment: results of the phase IV open-label SUNRISE study. *Br J Dermatol* (2019) 180(1):56–66. doi: 10.1111/bjd.16904

6. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. *J Allergy Clin Immunol* (2013) 132(1):101–9. doi: 10.1016/j.jaci.2013.05.013

7. Benyon RC, Robinson C, Church MK. Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. *Br J Pharmacol* (1989) 97(3):898–904. doi: 10.1111/j.1476-5381.1989.tb12030.x

8. Church MK, Benyon RC, Lowman MA, Hutson PA, Holgate ST. Allergy or inflammation? from neuropeptide stimulation of human skin mast cells to studies on the mechanism of the late asthmatic response. *Agents Actions* (1989) 26(1-2):22–30. doi: 10.1007/BF02126554

Funding

This work was funded by the National Natural Science Foundation of China (NSFC) (82201966), the Natural Science Basic Research Program of Shaanxi (2023-JC-QN-0924) to Zhao Wang, and the NSFC (82273526 and 82073451) to SG.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1207249/full#supplementary-material

9. Vena GA, Cassano N, Di Leo E, Calogiuri GF, Nettis E. Focus on the role of substance p in chronic urticaria. *Clin Mol Allergy* (2018) 16:24. doi: 10.1186/s12948-018-0101-z

10. Metz M, Krull C, Hawro T, Saluja R, Groffik A, Stanger C, et al. Substance p is upregulated in the serum of patients with chronic spontaneous urticaria. *J Invest Dermatol* (2014) 134(11):2833–6. doi: 10.1038/jid.2014.226

11. McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. *Nature* (2015) 519(7542):237–41. doi: 10.1038/nature14022

12. Toscano A, Elst J, Van Gasse AL, Beyens M, van der Poorten ML, Bridts CH, et al. Mas-related G protein-coupled receptor MRGPRX2 in human basophils: expression and functional studies. *Front Immunol* (2022) 13:1026304. doi: 10.3389/fmmu.2022.1026304

13. Roy S, Chompunud Na Ayudhya C, Thapaliya M, Deepak V, Ali H. Multifaceted MRGPRX2: new insight into the role of mast cells in health and disease. *J Allergy Clin Immunol* (2021) 148(2):293–308. doi: 10.1016/j.jaci.2021.03.049

14. Gaudenzio N, Sibilano R, Marichal T, Starkl P, Reber LL, Cenac N, et al. Different activation signals induce distinct mast cell degranulation strategies. *J Clin Invest* (2016) 126(10):3981–98. doi: 10.1172/JCI85538

15. Chen YC, Chang YC, Chang HA, Lin YS, Tsao CW, Shen MR, et al. Differential Ca(2+) mobilization and mast cell degranulation by FcepsilonRI- and GPCR-mediated signaling. *Cell Calcium* (2017) 67:31–9. doi: 10.1016/j.ceca.2017.08.002

16. Ma HT, Beaven MA. Regulation of Ca2+ signaling with particular focus on mast cells. Crit Rev Immunol (2009) 29(2):155-86. doi: 10.1615/CritRevImmunol.v29.i2.40

17. Ali H, Maeyama K, Sagi-Eisenberg R, Beaven MA. Antigen and thapsigargin promote influx of Ca2+ in rat basophilic RBL-2H3 cells by ostensibly similar mechanisms that allow filling of inositol 1,4,5-trisphosphate-sensitive and mitochondrial Ca2+ stores. *Biochem J* (1994) 304(Pt 2):431–40. doi: 10.1042/bj3040431

18. Ding Y, Che D, Li C, Cao J, Wang J, Ma P, et al. Quercetin inhibits Mrgprx2induced pseudo-allergic reaction *via* PLCgamma-IP3R related Ca(2+) fluctuations. *Int Immunopharmacol* (2019) 66:185–97. doi: 10.1016/j.intimp.2018.11.025

19. Kushnir A, Wajsberg B, Marks AR. Ryanodine receptor dysfunction in human disorders. *Biochim Biophys Acta Mol Cell Res* (2018) 1865(11 Pt B):1687-97. doi: 10.1016/j.bbamcr.2018.07.011

20. Yamaguchi N. Molecular insights into calcium dependent regulation of ryanodine receptor calcium release channels. *Adv Exp Med Biol* (2020) 1131:321–36. doi: 10.1007/978-3-030-12457-1_13

21. Lanner JT, Georgiou DK, Joshi AD, Hamilton SL. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. *Cold Spring Harb Perspect Biol* (2010) 2(11):a003996. doi: 10.1101/cshperspect.a003996

22. Takei M, Ueno M, Endo K. Effect of ryanodine on histamine release from rat peritoneal mast cells induced by anti-IgE. *J Pharm Pharmacol* (1992) 44(6):523–5. doi: 10.1111/j.2042-7158.1992.tb03660.x

23. Ichigi J. Histamine release from mast cells of EAE rats by gi protein-dependent and IgE-dependent pathways. J Mol Neurosci (1999) 13(1-2):93–9. doi: 10.1385/JMN:13:1-2:93

24. Zhao F, Li P, Chen SR, Louis CF, Fruen BR. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. *Mol Mech isoform selectivity J Biol Chem* (2001) 276 (17):13810-6. doi: 10.1074/jbc.M006104200

25. Takei M, Urashima H, Endo K. Effect of dantrolene on histamine release from rat peritoneal mast cells. *Agents Actions* (1991) 32(3-4):213-6. doi: 10.1007/BF01980876

26. Essin K, Gollasch M. Role of ryanodine receptor subtypes in initiation and formation of calcium sparks in arterial smooth muscle: comparison with striated muscle. *J BioMed Biotechnol* (2009) 2009:135249. doi: 10.1155/2009/135249

27. Uchinoumi H, Yang Y, Oda T, Li N, Alsina KM, Puglisi JL, et al. CaMKIIdependent phosphorylation of RyR2 promotes targetable pathological RyR2 conformational shift. *J Mol Cell Cardiol* (2016) 98:62-72. doi: 10.1016/ j.yjmcc.2016.06.007

28. Chaki S, Alkanfari I, Roy S, Amponnawarat A, Hui Y, Oskeritzian CA, et al. Inhibition of orai channel function regulates mas-related G protein-coupled receptormediated responses in mast cells. *Front Immunol* (2021) 12:803335. doi: 10.3389/ fimmu.2021.803335

29. Wajdner HE, Farrington J, Barnard C, Peachell PT, Schnackenberg CG, Marino JPJr., et al. Orai and TRPC channel characterization in FcepsilonRI-mediated calcium signaling and mediator secretion in human mast cells. *Physiol Rep* (2017) 5(5). doi: 10.14814/phy2.13166

 Rice LV, Bax HJ, Russell LJ, Barrett VJ, Walton SE, Deakin AM, et al. Characterization of selective calcium-release activated calcium channel blockers in mast cells and T-cells from human, rat, mouse and guinea-pig preparations. *Eur J Pharmacol* (2013) 704(1-3):49–57. doi: 10.1016/j.ejphar.2013.02.022

31. Akoto C, Willis A, Banas CF, Bell JA, Bryant D, Blume C, et al. IL-33 induces an antiviral signature in mast cells but enhances their permissiveness for human rhinovirus infection. *Viruses* (2022) 14(11). doi: 10.3390/v14112430

32. Babina M. The pseudo-allergic/neurogenic route of mast cell activation via MRGPRX2: discovery, functional programs, regulation, relevance to disease, and relation with allergic stimulation. *Itch* (2020) 5(2):e32. doi: 10.1097/itx.00000000000032

33. Kuhn H, Kolkhir P, Babina M, Dull M, Frischbutter S, Fok JS, et al. Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies. *J Allergy Clin Immunol* (2021) 147(2):456–69. doi: 10.1016/j.jaci.2020.08.027

34. Robinson C, Benyon C, Holgate ST, Church MK. The IgE- and calcium-dependent release of eicosanoids and histamine from human purified cutaneous mast cells. J Invest Dermatol (1989) 93(3):397–404. doi: 10.1016/0022-202X(89)90066-3

35. Blank U, Huang H, Kawakami T. The high affinity IgE receptor: a signaling update. *Curr Opin Immunol* (2021) 72:51-8. doi: 10.1016/j.coi.2021.03.015

36. Park DJ, Min HK, Rhee SG. IgE-induced tyrosine phosphorylation of phospholipase c-gamma 1 in rat basophilic leukemia cells. *J Biol Chem* (1991) 266 (36):24237–40. doi: 10.1016/S0021-9258(18)54217-4

37. Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. *Nat Rev Immunol* (2006) 6(3):218–30. doi: 10.1038/nri1782

38. Vig M, Kinet JP. Calcium signaling in immune cells. *Nat Immunol* (2009) 10 (1):21–7. doi: 10.1038/ni.f.220

39. Occhiuto CJ, Kammala AK, Yang C, Nellutla R, Garcia M, Gomez G, et al. Storeoperated calcium entry *via* STIM1 contributes to MRGPRX2 induced mast cell functions. *Front Immunol* (2019) 10:3143. doi: 10.3389/fimmu.2019.03143

40. Wang Z, Franke K, Bal G, Li Z, Zuberbier T, Babina M. MRGPRX2-mediated degranulation of human skin mast cells requires the operation of g(alphai), g(alphaq), ca++ channels, ERK1/2 and PI3K-interconnection between early and late signaling. *Cells* (2022) 11(6). doi: 10.3390/cells11060953

41. Brini M, Cali T, Ottolini D, Carafoli E. Intracellular calcium homeostasis and signaling. *Met Ions Life Sci* (2013) 12:119-68. doi: 10.1007/978-94-007-5561-1_5

42. Yoshimaru T, Suzuki Y, Inoue T, Ra C. L-type Ca2+ channels in mast cells: activation by membrane depolarization and distinct roles in regulating mediator release from store-operated Ca2+ channels. *Mol Immunol* (2009) 46(7):1267–77. doi: 10.1016/j.molimm.2008.11.011

43. Wang N, Wang J, Zhang Y, Zeng Y, Hu S, Bai H, et al. Imperatorin ameliorates mast cell-mediated allergic airway inflammation by inhibiting MRGPRX2 and CamKII/ERK signaling pathway. *Biochem Pharmacol* (2021) 184:114401. doi: 10.1016/j.bcp.2020.114401

44. Luo X, Chen J, Yang H, Hu X, Alphonse MP, Shen Y, et al. Dendritic cell immunoreceptor drives atopic dermatitis by modulating oxidized CaMKII-involved mast cell activation. *JCI Insight* (2022) 7(5). doi: 10.1172/jci.insight.152559

45. Qu J, Do DC, Zhou Y, Luczak E, Mitzner W, Anderson ME, et al. Oxidized CaMKII promotes asthma through the activation of mast cells. *JCI Insight* (2017) 2(1): e90139. doi: 10.1172/jci.insight.90139

46. Franke K, Wang Z, Zuberbier T, Babina M. Cytokines stimulated by IL-33 in human skin mast cells: involvement of NF-kappaB and p38 at distinct levels and potent Co-operation with FcepsilonRI and MRGPRX2. *Int J Mol Sci* (2021) 22(7). doi: 10.3390/ijms22073580

47. Babina M, Wang Z, Franke K, Zuberbier T. Thymic stromal lymphopoietin promotes MRGPRX2-triggered degranulation of skin mast cells in a STAT5-dependent manner with further support from JNK. *Cells* (2021) 10(1). doi: 10.3390/cells10010102

48. Supajatura V, Ushio H, Nakao A, Akira S, Okumura K, Ra C, et al. Differential responses of mast cell toll-like receptors 2 and 4 in allergy and innate immunity. *J Clin Invest* (2002) 109(10):1351–9. doi: 10.1172/JCI0214704

49. Babina M, Wang Z, Franke K, Guhl S, Artuc M, Zuberbier T. Yin-yang of IL-33 in human skin mast cells: reduced degranulation, but augmented histamine synthesis through p38 activation. *J Invest Dermatol* (2019) 139(7):1516–25 e3. doi: 10.1016/jid.2019.01.013

50. Baba Y, Nishida K, Fujii Y, Hirano T, Hikida M, Kurosaki T. Essential function for the calcium sensor STIM1 in mast cell activation and anaphylactic responses. *Nat Immunol* (2008) 9(1):81–8. doi: 10.1038/ni1546

51. Wang Z, Franke K, Zuberbier T, Babina M. Cytokine stimulation by MRGPRX2 occurs with lower potency than by FcepsilonRI aggregation but with similar dependence on the extracellular signal-regulated kinase 1/2 module in human skin mast cells. J Invest Dermatol (2022) 142(2):414–24 e8. doi: 10.1016/j.jid.2021.07.153

52. Park YJ, Yoo SA, Kim M, Kim WU. The role of calcium-Calcineurin-NFAT signaling pathway in health and autoimmune diseases. *Front Immunol* (2020) 11:195. doi: 10.3389/fimmu.2020.00195

53. Watson CJF, Maguire ARR, Rouillard MM, Crozier RWE, Yousef M, Bruton KM, et al. TAK1 signaling activity links the mast cell cytokine response and degranulation in allergic inflammation. *J Leukoc Biol* (2020) 107(4):649–61. doi: 10.1002/JLB.2A0220-401RR

54. Kim SI, Choi ME. TGF-beta-activated kinase-1: new insights into the mechanism of TGF-beta signaling and kidney disease. *Kidney Res Clin Pract* (2012) 31(2):94–105. doi: 10.1016/j.krcp.2012.04.322

55. Denda S, Kumamoto J, Takei K, Tsutsumi M, Aoki H, Denda M. Ryanodine receptors are expressed in epidermal keratinocytes and associated with keratinocyte differentiation and epidermal permeability barrier homeostasis. *J Invest Dermatol* (2012) 132(1):69–75. doi: 10.1038/jid.2011.256

56. Elferink JG, De Koster BM. Ryanodine as inhibitor of chemotactic peptideinduced chemotaxis in human neutrophils. *Biochem Pharmacol* (1995) 50(7):975–9. doi: 10.1016/0006-2952(95)00222-L